Formulated as a pro-drug and in a unique hypotonic formulation, Omnaris[R] addresses some important improvements on allergic rhinitis treatments such as: drug activation on the target cells, fast onset of action (studies have shown onset of action within 1 to 6 hours), increased absorption of ciclesonide and longer retention in the nasal mucosa compared to isotonic formulations, low systemic availability (1 percent) and low spray volume leading to a safety and tolerability profile compared to placebo, convenience of once daily dosage and efficacy in all main allergic rhinitis symptoms (runny nose, itchy nose, sneezing and nasal congestion).
What does CIC stand for?
CIC stands for Ciclesonide
This definition appears frequently and is found in the following Acronym Finder categories:
- Science, medicine, engineering, etc.
See other definitions of CIC
We have 692 other meanings of CIC in our Acronym Attic
- Chico (Amtrak station code; Chico, CA)
- Chico, CA, USA - Chico Municipal Air Terminal (Airport Code)
- Children in Crisis, Inc.
- China Investment Corporation (wealth fund)
- Chinese Institute of Communication
- Choices in Childbirth (New York, NY)
- Christ I'm Confused
- Christians in Commerce (various locations)
- Chronic Idiopathic Constipation
- Church Insurance Company
- Cincinnati Insurance Company (Ohio)
- Cinema International Corporation (film distribution; various locations)
- Circuit Identification Code
- Circuit Identifier Code
- Circulating Immune Complex
- Cisco Info Center
- Cisco Integrated Client (VPN client-softwares' built-in firewall)
- Citizens Information Centre (Ireland)
- Citizens' Investigative Commission (private action group)
- Citizenship and Immigration Canada
Samples in periodicals archive:
Currently marketed products include LUNESTA brand eszopiclone, XOPENEX brand levalbuterol HCl Inhalation Solution, XOPENEX HFA brand levalbuterol tartrate Inhalation Aerosol, BROVANA brand arformoterol tartrate Inhalation Solution, OMNARIS brand ciclesonide Nasal Spray and ALVESCO brand ciclesonide HFA Inhalation Aerosol.
Ciclesonide (Alvesco) the newest corticosteroid on the market received FDA approval in January of this year.
Poster Presentations by Sunovion at AAAAI: * A Post-hoc Analysis of Improvement in Individual Nasal Symptoms by Their Baseline Severity Following Treatment with Ciclesonide Hydrofluoroalkane Nasal Aerosol in Patients with Seasonal Allergic Rhinitis (Poster #668) In two randomized, double-blind, placebo-controlled Phase III SAR studies that enrolled 918 patients 12 to 65 years of age with a 2 year history of SAR, patients were given ZETONNA 74 mcg [CIC-HFA (37 mcg/actuation nostril)] or placebo, once daily for two weeks.
Long-term safety and efficacy of intranasal ciclesonide in adult and adolescent patients with perennial allergic rhinitis.
and Nycomed announced an exclusive development, marketing and commercialization agreement for ciclesonide in the United States.
the exclusive development, marketing and commercialisation rights for Ciclesonide in the United States.
MUNICH, Germany, September 4 /PRNewswire/ -- - Lower dose of ciclesonide effectively controls asthma symptoms and maintains lung function New efficacy data was presented for the first time at the 16th Annual European Respiratory Society (ERS) Congress confirming that a lower dose, or "stepping-down" to ciclesonide (Alvesco(R)), a once-daily, novel, inhaled corticosteroid (ICS) therapy for the treatment of asthma, is an equally effective maintenance treatment as twice-daily fluticasone propionate, another available asthma therapy.